Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression

Clinical Colorectal Cancer

Volumn 9, Issue 4, 2010, Pages 255-259

  Lee Kong, Steven A ^a   Markowitz, Arnold J ^a   Glogowski, Emily ^a   Papadopoulos, Christopher ^a   Stadler, Zsofia ^a   Weiser, Martin R ^a   Temple, Larissa K ^a   Guillem, José G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Amsterdam II criteria; Bethesda Guidelines; Lynch syndrome; MMR loss

Indexed keywords

MISMATCH REPAIR PROTEIN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GROUPS BY AGE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PROSPECTIVE STUDY; PROTEIN DEPLETION; PROTEIN EXPRESSION;

EID: 77957814993     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.038     Document Type: Article

References (46)

1. Lynch HT, Watson P, Lanspa SJ, et al. Natural history of colorectal cancer in hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). Dis Colon Rectum 1988; 31:439-44.
2. Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorec-tal cancer syndrome: later age of onset. Gastroenterology 2005; 129:415-21.
3. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary non-polyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020-7.
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-32.
5. Lynch HT, Lynch JF, Lynch PM, et al. Hereditary colorectal cancer syndromes: molecu-lar genetics, genetic counseling, diagnosis and management. Fam Cancer 2008; 7:27-39.
6. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96:516-20.
7. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71:677-85.
8. Malkhosyan S, Rampino N, Yamamoto H, et al. Frameshift mutator mutations. Nature 1996; 382:499-500.
9. Peltomäki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collab-orative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113:1146-58.
10. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18:2193-200.
11. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, micro-satellite instability and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293:1986-94.
12. Stone JG, Robertson D, Houlston RS. Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer. J Clin Pathol 2001; 54:484-7.
13. Aaltonen LA, Peltomäki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994; 54:1645-8.
14. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34:424-5.
15. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collabora-tive group on HNPCC. Gastroenterology 1999; 116:1453-6.
16. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 2004; 96:261-8.
17. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352:1851-60.
18. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354:2751-63.
19. Stormorken AT, Bowitz-Lothe IM, Norèn T, et al. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer. J Clin Oncol 2005; 23:4705-12.
20. Wijnen J, Khan PM, Vasen H, et al. Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 1997; 61:329-35.
21. Nyström-Lahti M, Wu Y, Moisio AL, et al. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 1996; 5:763-9.
22. Moslein G, Tester DJ, Lindor NM, et al. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996; 5:1245-52.
23. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36:801-18.
24. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979-85.
25. Berg AO, Armstrong K, Botkin J, et al. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11:35-41.
26. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorec-tal cancer. Science 1993; 260:812-6.
27. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorec-tal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338:1481-7.
28. Lothe RA, Peltomäki P, Meling GI, et al. Genomic instability in colorectal cancer: rela-tionship to clinicopathological variables and family history Cancer Res 1993; 53:5849-52.
29. Lukish JR, Muro K, De Nobile J, et al. Prognostic significance of DNA replication er-rors in young patients with colorectal cancer. Ann Surg 1998; 227:51-6.
30. Liu B, Farrington SM, Petersen GM, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995; 1:348-52.
31. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20:1043-8.
32. Debniak T, Kurzawski G, Gorski B, et al. Value of pedigree/clinical data, immunohis-tochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 2000; 36:49-54.
33. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159:2107-16.
34. Acharya S, Wilson T, Gradia S, et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996; 93:13629-34.
35. Ruo L, Cellini C, La-Calle JP, et al. Limitations of family cancer history assessment at initial surgical consultation. Dis Colon Rectum 2001; 44:98-104.
36. Shia J, Ellis NA, Paty PB, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003; 27:1407-17.
37. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005; 23:6524-32.
38. Niessen RC, Berends MJ, Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary nonpolyposis colorectal cancer. Gut 2006; 55:1781-8.
39. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical out-come in young patients with colorectal cancer. N Engl J Med 2000; 342:69-77.
40. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry J Mol Diagn 2008; 10:293-300.
41. Barrow E, Mc Mahon R, Evans DG, et al. Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. Br J Surg 2008; 95:868-75.
42. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho Oncology 2005; 14:1060-74.
43. Hadley DW, Jenkins JF, Dimond E, et al. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2004; 22:39-44.
44. Bessa X, Ballesté B, Andreu M, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 2008; 6:206-14.
45. Schofield L, Watson N, Grieu F, et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 2009; 124:1097-102.
46. Jenkins MA, Dowty JG, Hopper JL, et al. Molecular screening of all colorectal tumors diagnosed before age 50 years followed by genetic testing efficiently identifies Lynch syndrome cases. Int J Cancer 2009; 124:x-i.